A phase IIII study of AMN107, a novel aminopyrimidine inhibitor of bcr-abl, on a continuous daily dosing schedule in adult patients (pts) with imatinib-resistant advanced phase chronic myeloid leukemia (CML) or relapsed/refractory Philadelphia chromosome (Ph plus ) acute llymphocytic leukemia (ALL).

被引：23

作者：

Giles, F

Kantarjian, H

Wassmann, B

Cortes, J

O'Brien, S

Tanaka, C

Rae, P

Mietlowski, W

Romano, A

Alland, L

Dugan, M

Albitar, M

Ottmann, O

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] JW Goethe Univ, Frankfurt, Germany

[3] Novartis Pharmaceut Corp, E Hanover, NJ USA

[4] Quest Diagnost Nichols Inst, San Juan Capistrano, CA USA

来源：

关键词：

D O I：

10.1182/blood.V104.11.22.22

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：10A / 11A

页数：2